SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-303604
Filing Date
2020-11-25
Accepted
2020-11-25 16:00:30
Documents
3
Period of Report
2020-11-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d10278d8k.htm 8-K 25159
2 EX-4.1 d10278dex41.htm EX-4.1 70564
3 EX-10.1 d10278dex101.htm EX-10.1 341609
  Complete submission text file 0001193125-20-303604.txt   438664
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 201350462
SIC: 2834 Pharmaceutical Preparations